Imaging genomics and response to treatment with antipsychotics in schizophrenia

NeuroRx

Volumn 3, Issue 1, 2006, Pages 117-130

  Blasi, Giuseppe ^a,b   Bertolino, Alessandro ^a,b,c  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Antipsychotics; COMT; DISC1; fMRI; GRM3; Imaging genomics; PET; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; CLOZAPINE; DRUG RECEPTOR; FLUORODEOXYGLUCOSE F 18; HALOPERIDOL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

BEHAVIOR; BRAIN FUNCTION; CLINICAL TRIAL; COMT GENE; DISC1 GENE; DRUG RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; GRM3 GENE; HUMAN; IN VIVO STUDY; MEDICAL RESEARCH; MENTAL DISEASE; NEUROBIOLOGY; NEUROIMAGING; PHARMACOGENETICS; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PUBLIC HEALTH; REVIEW; SCHIZOPHRENIA;

EID: 33244479185     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1016/j.nurx.2005.12.001     Document Type: Article

References (110)

1. McGuffin P, Riley B, Plomin R. Genomics and behavior. Toward behavioral genomics. Science 5507:1232-1249, 2001.
2. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 1:40-68, 2005.
3. Lewis CM, Levinson DF, Wise LH, Delisi LE, Straub RE, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder. Part II: schizophrenia. Am J Hum Genet 1:34-48, 2003.
4. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 4:405-411, 2002.
5. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 7:660-669, 1987.
6. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 7:2697-2708, 1998.
7. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2:389-395, 2002.
8. Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H, et al. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 10:1790-1799, 2004.
9. Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ. Catechol-o- methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 23:5331-5335, 2004.
10. Liljequist R, Haapalinna A, Ahlander M, Li YH, Mannisto PT. Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav Brain Res 2:195-202, 1997.
11. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 17:9991-9996, 1998.
12. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 4:593-628, 1999.
13. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 1:1-58, 2004.
14. Goldman-Rakic PS. The cortical dopamine system: role in memory and cognition. Adv Pharmacol 707-711, 1998.
15. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 12:6917-6922, 2001.
16. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 9:889-896, 2003.
17. Blasi G, Mattay VS, Bertolino A, Elvevag B, Callicott JH, Das S, et al. Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci 20:5038-5045, 2005.
18. Bearden CE, Jawad AF, Lynch DR, Sokol S, Kanes SJ, McDonald-McGinn DM, et al. Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22q11.2 deletion syndrome. Am J Psychiatry 9:1700-1702, 2004.
19. Diamond A, Briand L, Fossella J, Gehlbach L. Genetic and neurochemical modulation of prefrontal cognitive functions in children. Am J Psychiatry 1:125-132, 2004.
20. Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 11: 1078-1092, 2000.
21. Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry 2:99-109, 2000.
22. Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, et al. Interaction of COMT Val108/158 Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 10:1798-1805, 2004.
23. 158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol Psychiatry 3:229:287-298, 2005.
24. St Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G, et al. Association within a family of a balanced autosomal translocation with major mental illness. Lancet 8706: 13-16, 1990.
25. Devon RS, Anderson S, Teague PW, Burgess P, Kipari TM, Semple CA, et al. Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorder. Psychiatr Genet 2:71-78, 2001.
26. Hennah W, Varilo T, Kestila M, Paunio T, Arajarvi R, Haukka J, et al. Haplotype transmission analysis provides evidence of association for DISCI to schizophrenia and suggests sex-dependent effects. Hum Mol Genet 23:3151-3159, 2003.
27. Ekelund J, Hennah W, Hiekkalinna T, Parker A, Meyer J, Lonnqvist J, et al. Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol Psychiatry 11:1037-1041, 2004.
28. Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH, et al. Disrupted in Schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 5:862-872, 2004.
29. Sachs NA, Sawa A, Holmes SE, Ross CA, Delisi LE, Margolis RL. A frameshift mutation in disrupted in schizophrenia I in an American family with schizophrenia and schizoaffective disorder. Mol Psychiatry 10:758-764, 2005.
30. Thomson PA, Wray NR, Millar JK, Evans KL, Hellard SL, Condie A, et al. Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population. Mol Psychiatry 7:616, 657-668, 2005.
31. Morris JA, Kandpal G, Ma L, Austin CP. DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Hum Mol Genet 13:1591-1608, 2003.
32. Austin CP, Ky B, Ma L, Morris JA, Shughrue PJ. Expression of Disrupted-In-Schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development. Neuroscience 1:3-10, 2004.
33. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR, et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA 24:8627-8632, 2005.
34. Bunney BS, Chiodo LA, Grace AA. Midbrain dopamine system electrophysiological functioning: a review and new hypothesis. Synapse 2:79-94, 1991.
35. Deakin JF, Slater P, Simpson MD, Gilchrist AC, Skan WJ, Royston MC, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 6:1781-1786, 1989.
36. Nishikawa T, Takashima M, Toru M. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 3:245-250, 1983.
37. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 10:829-836, 1995.
38. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 3:889-907, 2000.
39. Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S, et al. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci 10: 2106-2118, 2003.
40. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 3:675-686, 1996.
41. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 5381:1349-1352, 1998.
42. Ohnuma T, Tessler S, Arai H, Faull RL, McKenna PJ, Emson PC. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res 1-2:24-31, 2000.
43. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 34:12604-12609, 2004.
44. Fujii Y, Shibata H, Kikuta R, Makino C, Tani A, Hirata N, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 2:71-76, 2003.
45. Chen Q, He G, Wu S, Xu Y, Feng G, Li Y, et al. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res 1:21-26, 2005.
46. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 12:1554-1563, 1996.
47. Marti SB, Cichon S, Propping P, Nothen M. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet 1:46-50, 2002.
48. Norton N, Williams HJ, Dwyer S, Ivanov D, Preece AC, Gerrish A, et al. No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry 1:23, 2005.
49. Lu B, Gottschalk W. Modulation of hippocampal synaptic transmission and plasticity by neurotrophins. Prog Brain Res 128: 231-241, 2000.
50. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 1:24-32, 2001.
51. Gottschalk W, Pozzo-Miller LD, Figurov A, Lu B. Presynaptic modulation of synaptic transmission and plasticity by brain-derived neurotrophic factor in the developing hippocampus. J Neurosci 17:6830-6839, 1998.
52. Gottschalk WA, Jiang H, Tartaglia N, Feng L, Figurov A, Lu B. Signaling mechanisms mediating BDNF modulation of synaptic plasticity in the hippocampus. Learn Mem 3:243-256, 1999.
53. Jovanovic JN, Czernik AJ, Fienberg AA, Greengard P, Sihra TS. Synapsins as mediators of BDNF-enhanced neurotransmitter release. Nat Neurosci 4:323-329, 2000.
54. Pozzo-Miller LD, Gottschalk W, Zhang L, McDermott K, Du J, Gopalakrishnan R, et al. Impairments in high-frequency transmission, synaptic vesicle docking, and synaptic protein distribution in the hippocampus of BDNF knockout mice. J Neurosci 12: 4972-4983, 1999.
55. Xu B, Gottschalk W, Chow A, Wilson RI, Schnell E, Zang K, et al. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci 18:6888-6897, 2000.
56. Linnarsson S, Bjorklund A, Ernfors P. Learning deficit in BDNF mutant mice. Eur J Neurosci 12:2581-2587, 1997.
57. Minichiello L, Korte M, Wolfer D, Kuhn R, Unsicker K, Cestari V, et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 2:401-414, 1999.
58. Mizuno M, Yamada K, Olariu A, Nawa H, Nabeshima T. Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. J Neurosci 18:7116-7121, 2000.
59. Angelucci F, Brene S, Mathe AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 4:345-352, 2005.
60. Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJ, Frank JA, et al. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatry 10:941-950, 1998.
61. Hattori M, Kunugi H, Akahane A, Tanaka H, Ishida S, Hirose T, et al. Novel polymorphisms in the promoter region of the neurotrophin-3 gene and their associations with schizophrenia. Am J Med Genet 3:304-309, 2002.
62. Jonsson E, Brene S, Zhang XR, Nimgaonkar VL, Tylec A, Schalling M, et al. Schizophrenia and neurotrophin-3 alleles. Acta Psychiatr Scand 5:414-419, 1997.
63. Szekeres G, Juhasz A, Rimanoczy A, Keri S, Janka Z. The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophr Res 1:15-18, 2003.
64. 66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2:257-269, 2003.
65. Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 2:208-212, 2005.
66. Szczepankiewicz A, Skibinska M, Czerski PM, Kapelski P, Leszczynska-Rodziewicz A, Slopien A, et al. No association of the brain-derived neurotrophic factor (BDNF) gene C-270T polymorphism with schizophrenia. Schizophr Res 2-3:187-193, 2005.
67. de Krom M, Bakker SC, Hendriks J, van Elburg A, Hoogendoorn M, Verduijn W, et al. Polymorphisms in the brain-derived neurotrophic factor gene are not associated with either anorexia nervosa or schizophrenia in Dutch patients. Psychiatr Genet 2:81, 2005.
68. 66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 17:6690-6694, 2003.
69. 66met polymorphism and variation in human cortical morphology. J Neurosci 45:10099-10102, 2004.
70. 66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 7:631-636, 2005.
71. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 5:780-796, 2004.
72. Schafer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 5:802-804, 2001.
73. Suzuki A, Mihara K, Kondo T, Tanaka O, Nagashima U, Otani K, et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 4:335-341, 2000.
74. Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Ishida M, Furukori H, et al. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 6:545-550, 2001.
75. Arranz MJ, Li T, Munro J, Liu X, Murray R, Collier DA, et al. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 6:481-484, 1998.
76. Kapur S, Agid O, Mizrahi R, Li M. How anitpsychotics work-from receptors to reality. NeuroRx 3:10-21, 2006.
77. Gessa GL, Devoto P, Diana M, Flore G, Melis M, Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 6:642-649, 2000.
78. Diaz-Asper C, Goldberg T. COMT polymorphism and prefrontal cognitive function. NeuroRx 3:97-105, 2006.
79. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF, et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 9:677-682, 2004.
80. Bishop JR, Ellingrod VL, Moline J, Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 77:253-60, 2005.
81. Krebs MO, Guillin O, Bourdell MC, Schwartz JC, Olie JP, Poirier MF, et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 5:558-562, 2000.
82. 66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 3:206-208, 2003.
83. Anttila S, Illi A, Kampman O, Mattila KM, Lehtimaki T, Leinonen E. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J Neural Transm 7:885-890, 2005.
84. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 8:1200-1204, 1999.
85. Scheepers FE, de Wied CC, Hulshoff Pol HE, van de Flier W, van der Linden JA, Kahn RS. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 1:47-54, 2001.
86. Scheepers FE, Gispen de Wied CC, Hulshoff Pol HE, Kahn RS. Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia. Am J Psychiatry 4:644-646, 2001.
87. Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Smith GN, Goghari VM, et al. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Am J Psychiatry 4:625-631, 2001.
88. Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Smith GN, Goghari VM, et al. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am J Psychiatry 10:1829-1836, 2004.
89. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 4:361-370, 2005.
90. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of Haloperidol and Olanzapine in Macaque monkeys. Neuropsychopharmacology 9:1649-1661, 2005.
91. Fukuzako H, Fukuzako T, Kodama S, Hashiguchi T, Takigawa M, Fujimoto T. Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients. Neuropsychopharmacology 4:542-549, 1999.
92. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, et al. The effect of treatment with antipsychotic drugs on brain N- acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 1:39-46, 2001.
93. Liddle PF, Lane CJ, Ngan ET. Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. Br J Psychiatry 402-407, 2000
94. Bartlett EJ, Brodie JD, Simkowitz P, Schlosser R, Dewey SL, Lindenmayer JP, et al. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiatry 3:337-343, 1998.
95. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, et al. Cerebral metabolism and risperidone treatment in schizophrenia. Schiiophr Res 1:1-7, 2003.
96. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, et al. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychophamacology (Berl) 1:17-26, 2005.
97. Rodriguez VM, Andree RM, Castejon MJ, Zamora ML, Alvaro PC, Delgado JL, et al. Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A 99mTc-HMPAO study. Psychiatry Res 1:51-61, 1997.
98. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Frey KN, Hardin M, et al. Clozapine but not haloperidol re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology 1:171-178, 2004.
99. Molina V, Gispert JD, Reig S, Pascau J, Martinez R, Sanz J, et al. Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia. Int Clin Psychopharmacol 1:13-18, 2005.
100. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 23:13432-13437, 1999.
101. Mattay VS, Callicott JH, Bertolino A, Santha AK, Tallent KA, Goldberg TE, et al. Abnormal functional lateralization of the sensorimotor cortex in patients with schizophrenia. Neuroreport 13:2977-2984, 1997.
102. Stephan KE, Magnotta VA, White T, Arndt S, Flaum M, O'Leary DS, et al. Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol Med 6:1065-1078, 2001.
103. Bertolino A, Blasi G, Caforio G, Latorre V, De Candia M, Rubino V, et al. Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine. Biol Psychiatry 3:190-197, 2004.
104. Stip E, Fahim C, Mancini-Marie A, Bentaleb LA, Mensour B, Mendrek A, et al. Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1:21-26, 2005.
105. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 1:109-113, 2003.
106. Bertolino A, Caforio G, Petruzzella V, Latorre V, Rubino V, Dimalta S, et al. GRM3 genotype and olanzapine treatment: Differential effects on prefrontal cortical function during working memory in patients with schizophrenia. Biol Psychiatry 8:S293, 2005.
107. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 9:3708-3719, 2002.
108. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O- methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 11:1943-1961, 2004.
109. Stahl S. Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx 3:3-9, 2006.
110. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci 7:325-335, 2004.